On 17 December 2010, orphan designation (EU/3/10/824) was granted by the European Commission to Merck KGaA, Germany, for N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl) amino] isonicotinamide hydrochloride for the treatment of acute myeloid leukaemia.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in July 2020 on request of the Sponsor.
EU/3/10/824: Public summary of opinion on orphan designation: N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino] isonicotinamide hydrochloride for the treatment of acute myeloid leukaemia (PDF/207.21 KB)
First published: 20/01/2011
Last updated: 12/08/2020
|Disease / condition||
Treatment of acute myeloid leukaemia
|Date of first decision||
|EU designation number||
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.